Neopharm KRX:092730KOSDAQ
네오팜 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Neopharm reported revenue of ₩43.6bn, up 36.2% year on year, and operating profit of ₩9.8bn. Neopharm (네오팜) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Revenue +30% Revenue & profit growth Op. margin 20%+ Screener
Neopharm quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩43.6bn | +36.2% | ₩9.8bn | ₩8.4bn |
| Q1 2026 | ₩36.2bn | +14.6% | ₩8.7bn | ₩8.6bn |
| Q4 2025 derived | ₩36.4bn | +7.0% | ₩7.2bn | ₩6.8bn |
| Q3 2025 | ₩32.2bn | +23.1% | ₩6.8bn | ₩6.9bn |
| Q2 2025 | ₩32.0bn | +4.4% | ₩7.0bn | ₩7.1bn |
| Q1 2025 | ₩31.6bn | +12.0% | ₩7.8bn | ₩7.1bn |
| Q4 2024 derived | ₩34.0bn | +25.0% | ₩6.7bn | ₩6.7bn |
| Q3 2024 | ₩26.2bn | +19.9% | ₩5.1bn | ₩4.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Neopharm top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Neopharm news Korean headlines
No articles yet.